“The State, via Bpifrance, will be a shareholder”, announced Antoine Armand on Sunday evening, on the social network
Opella markets Doliprane in particular. “We have obtained guarantees for the maintenance and development of Opella in France, writes Antoine Armand. Our demands on employment, production and investment will be respected. For Doliprane and other essential medicines in the country. »
Read also: Four questions to understand why Doliprane is considered so strategic for France
Job retention
The government is particularly concerned about maintaining employment on the Opella sites in Lisieux (Calvados) and Compiègne (Oise). He is also keen to ensure security of supply.
Remember that Sanofi plans to sell 50% of its subsidiary to the American investment fund CD & R. The State therefore intends to become a minority shareholder in the sold subsidiary, via the public investment bank Bpifrance.
“It is good that a public operator, like Bpifrance, can enter into the capital, Laurent Saint-Martin, the Budget Minister, declared on Sunday midday. This allows us to be on the board of directors, to be in governance to ensure that our conditions are maintained. »
The government did not specify how much this entry into capital would cost it. A very sensitive issue in the context of budgetary rigor. Ministers Antoine Armand and Marc Ferracci (Industry) are expected to provide more details during a press conference scheduled for Monday, October 21, at 8:30 a.m.
“A dreaded social breakdown”
At the Lisieux factory, which employs more than 250 people, the announcement of a possible sale to an American fund has caused great concern. Employees fear “a social breakdown” et “a relocation ».
France
Related News :